Compare AbbVie Inc (ABBV) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Valero Energy Corporation — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Valero Energy Corporation trades at $324.8 (market cap $90.68B). The key difference: AbbVie Inc is far larger — about 4.8× Valero Energy Corporation's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | VLO | |
|---|---|---|
Market Cap | $438.19B | $90.68B |
Sector | Health | Energy |
52-Week High | $263.58 | $323.92 |
52-Week Low | $197.38 | $133.38 |
Enterprise Value | $502.45B | $94.16B |
Dividend Yield | 2.79% | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Valero Energy (VLO) trades at $298.31, down 1.54% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 29.31% ROE and trades at a P/E of 12.44, below industry averages. Recent news highlights geopolitical tensions supporting refining margins, while Q2 2026 earnings surged on strong refining and renewable diesel performance.
Outlook remains positive with a consensus price target of $324.27, implying 8.7% upside, but risks include volatile oil prices and declining revenue trends. Analyst sentiment is bullish with 55.55% buy ratings, though technical indicators suggest near-term caution amid bearish momentum signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
